https://peripazienti.roche.it2026-01-14https://peripazienti.roche.it/it/trials.html2025-06-06https://peripazienti.roche.it/it/trials/uncategorized.html2018-12-20https://peripazienti.roche.it/it/trials/cancer/solid-tumors/a-study-of-ro6958688-in-participants-with-locally-advan-08287.html2024-08-31https://peripazienti.roche.it/it/trials/cancer/solid-tumors/tumor-agnostic-precision-immuno-oncology-and-somatic-ta-50851.html2025-03-27https://peripazienti.roche.it/it/trials/cancer/solid-tumors/a-study-evaluating-the-safety--pharmacokinetics--and-ef-29617.html2025-03-27https://peripazienti.roche.it/it/trials/cancer/high-grade-glioma.html2020-09-01https://peripazienti.roche.it/it/trials/cancer/oc1.html2023-05-10https://peripazienti.roche.it/it/trials/cancer/bc/a-study-to-evaluate-the-pharmacokinetics--efficacy--and-safety-o.html2022-10-29https://peripazienti.roche.it/it/trials/cancer/bc/a-study-evaluating-safety--pharmacokinetics--and-therapeutic-act.html2024-08-31https://peripazienti.roche.it/it/trials/cancer/bc/a-study-of-ipatasertib-in-combination-with-paclitaxel-as-a-treat.html2024-09-18https://peripazienti.roche.it/it/trials/cancer/bc/a-study-comparing-atezolizumab--anti-pd-l1-antibody--in-68166.html2024-09-18https://peripazienti.roche.it/it/trials/cancer/bc/a-study-of-atezolizumab-and-paclitaxel-versus-placebo-and-paclit.html2024-08-30https://peripazienti.roche.it/it/trials/cancer/bc/a-study-of-the-efficacy-and-safety-of-atezolizumab-plus-chemothe.html2024-11-09https://peripazienti.roche.it/it/trials/cancer/bc/a-study-to-evaluate-the-efficacy-and-safety-of-trastuzu-87572.html2026-03-25https://peripazienti.roche.it/it/trials/cancer/bc/a-study-to-evaluate-the-efficacy-and-safety-of-atezoliz-39916.html2024-11-06https://peripazienti.roche.it/it/trials/cancer/bc/a-study-of-trastuzumab-emtansine-versus-trastuzumab-as-adjuvant-.html2025-03-27https://peripazienti.roche.it/it/trials/cancer/bc/a-study-evaluating-the-efficacy-and-safety-of-gdc-0077--75564.html2025-03-27https://peripazienti.roche.it/it/trials/cancer/bc/a-study-of-trastuzumab-emtansine--kadcyla--plus-pertuzu-91245.html2024-08-31https://peripazienti.roche.it/it/trials/cancer/bc/a-study-of-pertuzumab-in-combination-with-trastuzumab---50542.html2024-08-31https://peripazienti.roche.it/it/trials/cancer/bc/a-study-of-atezolizumab--tecentriq--plus-nab-paclitaxel-22823.html2025-03-27https://peripazienti.roche.it/it/trials/cancer/bc/a-study-of-trastuzumab-emtansine-in-combination-with-at-19708.html2025-02-19https://peripazienti.roche.it/it/trials/cancer/bc/a-study-evaluating-the-efficacy-and-safety-of-adjuvant--70278.html2025-03-27https://peripazienti.roche.it/it/trials/cancer/leukemia/a-study-of-idasanutlin-with-cytarabine-versus-cytarabine-plus-pl.html2024-06-22https://peripazienti.roche.it/it/trials/cancer/leukemia/a-study-to-compare-the-efficacy-and-safety-of-a-combine-77420.html2025-01-14https://peripazienti.roche.it/it/trials/cancer/leukemia/a-study-evaluating-the-safety--efficacy--and-pharmacoki-80734.html2025-02-01https://peripazienti.roche.it/it/trials/cancer/oc/a-study-of-atezolizumab-versus-placebo-in-combination-with-pacli.html2024-08-30https://peripazienti.roche.it/it/trials/cancer/oc/a-study-evaluating-the-safety--pharmacokinetics-and-eff-46472.html2024-06-21https://peripazienti.roche.it/it/trials/cancer/crc/a-study-evaluating-the-safety-and-efficacy-of-targeted--57345.html2025-03-27https://peripazienti.roche.it/it/trials/cancer/pv/a-study-to-evaluate-the-efficacy--safety--pharmacokinetics-and-p.html2024-08-30https://peripazienti.roche.it/it/trials/cancer/a-study-in-participants-previously-enrolled-in-a-genentech-and-o.html2025-02-07https://peripazienti.roche.it/it/trials/cancer/bladder-cancer/study-of-atezolizumab-as-monotherapy-and-in-combination-with-pla.html2025-02-25https://peripazienti.roche.it/it/trials/cancer/bladder-cancer/a-study-of-atezolizumab-versus-placebo-as-adjuvant-ther-94959.html2025-03-27https://peripazienti.roche.it/it/trials/cancer/bladder-cancer/a-study-of-ro7247669-alone-or-in-combination-with-tirag-35445.html2025-02-07https://peripazienti.roche.it/it/trials/cancer/lung-cancer/a-study-of-atezolizumab-compared-with-chemotherapy-in-treatment-.html2024-10-24https://peripazienti.roche.it/it/trials/cancer/lung-cancer/a-study-to-evaluate-efficacy-and-safety-of-multiple-targeted-the.html2025-03-27https://peripazienti.roche.it/it/trials/cancer/lung-cancer/a-study-comparing-adjuvant-alectinib-versus-adjuvant-platinum-ba.html2025-02-06https://peripazienti.roche.it/it/trials/cancer/lung-cancer/a-study-of-neoadjuvant-atezolizumab-plus-chemotherapy-versus-pla.html2025-03-27https://peripazienti.roche.it/it/trials/cancer/lung-cancer/a-study-of-carboplatin-plus-etoposide-with-or-without-atezolizum.html2024-08-31https://peripazienti.roche.it/it/trials/cancer/lung-cancer/a-study-to-investigate-the-pharmacokinetics--efficacy---50110.html2025-03-27https://peripazienti.roche.it/it/trials/cancer/lung-cancer/a-study-of-atezolizumab-plus-carboplatin-and-etoposide--78663.html2026-02-27https://peripazienti.roche.it/it/trials/cancer/lung-cancer/a-study-of-atezolizumab-in-combination-with-carboplatin-17822.htmlhttps://peripazienti.roche.it/it/trials/cancer/lung-cancer/a-study-comparing-alectinib-with-crizotinib-in-treatmen-47622.html2025-03-27https://peripazienti.roche.it/it/trials/cancer/lung-cancer/a-study-of-atezolizumab-and-tiragolumab-compared-with-d-48756.html2025-03-27https://peripazienti.roche.it/it/trials/cancer/lung-cancer/a-study-of-tiragolumab-in-combination-with-atezolizumab-98469.htmlhttps://peripazienti.roche.it/it/trials/cancer/lung-cancer/a-study-of-atezolizumab-in-participants-with-programmed-13746.html2024-09-01https://peripazienti.roche.it/it/trials/cancer/lung-cancer/a-study-to-compare-the-efficacy-and-safety-of-entrectin-60665.html2025-03-27https://peripazienti.roche.it/it/trials/cancer/lung-cancer/a-study-to-evaluate-participant-and-healthcare-professi-70557.html2024-11-22https://peripazienti.roche.it/it/trials/cancer/lung-cancer/a-phase-iii--open-label-study-of-maintenance-lurbinecte-08813.html2025-03-13https://peripazienti.roche.it/it/trials/cancer/multiple-myeloma/a-study-evaluating-the-safety-and-pharmacokinetics-of-e-50454.html2025-03-27https://peripazienti.roche.it/it/trials/cancer/multiple-myeloma/a-study-evaluating-the-safety--pharmacokinetics--and-ac-86713.html2025-01-15https://peripazienti.roche.it/it/trials/cancer/multiple-myeloma/a-study-evaluating-the-efficacy-and-safety-of-cevostama-15661.html2025-02-19https://peripazienti.roche.it/it/trials/cancer/rcc/a-study-of-atezolizumab-plus-bevacizumab-versus-active--52983.html2025-03-27https://peripazienti.roche.it/it/trials/cancer/rcc/a-study-of-atezolizumab-in-combination-with-cabozantini-46186.html2025-01-15https://peripazienti.roche.it/it/trials/cancer/skin-cancer/a-study-evaluating-the-safety-and-efficacy-of-cobimetin-52731.html2024-06-21https://peripazienti.roche.it/it/trials/cancer/hepatocellular-carcinoma/a-study-of-atezolizumab-in-combination-with-bevacizumab-compared.html2024-09-18https://peripazienti.roche.it/it/trials/cancer/Head_and_Neck_Cancer/a-study-of-atezolizumab--antipd-l1-antibody--as-adjuvant-therapy.html2024-10-10https://peripazienti.roche.it/it/trials/cancer/Brain_Tumor/study-of-rxdx-101-in-children-with-recurrent-or-refractory-solid.html2025-03-27https://peripazienti.roche.it/it/trials/cancer/pancreatic-cancer.html2018-12-20https://peripazienti.roche.it/it/trials/cancer/a-phase-ii-randomized-study-comparing-the-efficacy-and-safety-of.html2026-03-09https://peripazienti.roche.it/it/trials/cancer/safety-and-pharmacokinetics-of-cobimetinib-in-pediatric-and-youn.html2024-08-31https://peripazienti.roche.it/it/trials/cancer/prostate-cancer/a-study-of-atezolizumab--anti-pd-l1-antibody--in-combination-wit.html2024-08-30https://peripazienti.roche.it/it/trials/cancer/prostate-cancer/ipatasertib-plus-abiraterone-plus-prednisone-prednisolone--relat.html2024-08-31https://peripazienti.roche.it/it/trials/cancer/prostate-cancer/a-study-evaluating-the-safety--efficacy-and-pharmacokin-79210.html2024-09-18https://peripazienti.roche.it/it/trials/cancer/gc.html2018-12-20https://peripazienti.roche.it/it/trials/cancer/a-study-of-atezolizumab-in-locally-advanced-or-metastat-72736.html2024-08-31https://peripazienti.roche.it/it/trials/cancer/fmi.html2024-11-13https://peripazienti.roche.it/it/trials/cancer/alk-rearranged-non-small-cell-lung-cancer.html2018-12-20https://peripazienti.roche.it/it/trials/cancer/non-hodgkins-lymphoma/a-study-to-evaluate-the-safety--pharmacokinetics-and-pr-54653.html2025-03-25https://peripazienti.roche.it/it/trials/cancer/non-hodgkins-lymphoma/a-study-of-atezolizumab-in-combination-with-either-obin-92178.html2026-03-25https://peripazienti.roche.it/it/trials/cancer/non-hodgkins-lymphoma/a-dose-escalation-study-of-ro7082859-as-a-single-agent-and-in-co.html2025-03-13https://peripazienti.roche.it/it/trials/cancer/non-hodgkins-lymphoma/an-open-label-phase-lb-study-of-ro7082859-and-atezolizumab-in-ad.html2020-11-05https://peripazienti.roche.it/it/trials/cancer/non-hodgkins-lymphoma/a-study-of-obinutuzumab--rituximab--polatuzumab-vedotin--and-ven.html2024-08-31https://peripazienti.roche.it/it/trials/cancer/non-hodgkins-lymphoma/a-study-comparing-the-efficacy-and-safety-of-polatuzumab-vedotin.html2023-04-12https://peripazienti.roche.it/it/trials/cancer/non-hodgkins-lymphoma/a-study-evaluating-the-efficacy-and-safety-of-mosunetuz-89423.html2025-03-27https://peripazienti.roche.it/it/trials/cancer/non-hodgkins-lymphoma/a-study-to-evaluate-the-safety-and-efficacy-of-polatuzu-71789.html2025-03-27https://peripazienti.roche.it/it/trials/cancer/non-hodgkins-lymphoma/a-study-to-evaluate-the-safety--tolerability--pharmacok-73268.html2024-09-18https://peripazienti.roche.it/it/trials/cancer/non-hodgkins-lymphoma/a-study-evaluating-the-safety--pharmacokinetics--and-ef-62272.html2025-01-11https://peripazienti.roche.it/it/trials/cancer/non-hodgkins-lymphoma/a-study-to-evaluate-glofitamab-as-a-single-agent-vs--in-75996.html2025-03-08https://peripazienti.roche.it/it/trials/cancer/a-study-of-the-safety--pharmacokinetics--and-therapeuti-98047.html2024-08-31https://peripazienti.roche.it/it/trials/cancer/endometrial-cancer/a-study-of-giredestrant-in-participants-with-grade-1-en-08530.html2025-01-23https://peripazienti.roche.it/it/trials/cancer/thyroid-cancer.html2021-05-04https://peripazienti.roche.it/it/trials/cancer/melanoma.html2021-11-11https://peripazienti.roche.it/it/trials/cancer/a-study-exploring-the-safety-and-efficacy-of-atezolizumab-in-com.html2023-04-12https://peripazienti.roche.it/it/trials/autoimmune-disorder/giant-cell-arteritis.html2019-12-18https://peripazienti.roche.it/it/trials/autoimmune-disorder/ra/study-to-compare-the-efficacy-of-tocilizumab-with-or-without-glu.html2024-08-30https://peripazienti.roche.it/it/trials/autoimmune-disorder/sjogren-s-syndrome.html2018-12-20https://peripazienti.roche.it/it/trials/autoimmune-disorder/ulcerative-colitis/a-study-comparing-the-efficacy-and-safety-of-etrolizumab-to-infl.html2024-09-01https://peripazienti.roche.it/it/trials/autoimmune-disorder/ulcerative-colitis/a-study-to-evaluate-the-efficacy--safety--and-pharmacokinetics-o.html2024-08-31https://peripazienti.roche.it/it/trials/autoimmune-disorder/ulcerative-colitis/study-for-participants-with-ulcerative-colitis-previously-enroll.html2024-10-24https://peripazienti.roche.it/it/trials/autoimmune-disorder/ulcerative-colitis/an-extension-study-to-evaluate-the-long-term-safety-and-37359.html2024-08-31https://peripazienti.roche.it/it/trials/autoimmune-disorder/crohn-s-disease/a-study-to-assess-whether-etrolizumab-is-a-safe-and-effective-tr.html2024-09-09https://peripazienti.roche.it/it/trials/autoimmune-disorder/crohn-s-disease/a-study-to-assess-the-efficacy-and-safety-of-induction--32899.html2025-10-15https://peripazienti.roche.it/it/trials/autoimmune-disorder/crohn-s-disease/a-study-to-assess-the-efficacy-and-safety-of-induction--94939.html2025-10-16https://peripazienti.roche.it/it/trials/autoimmune-disorder/sle/a-study-to-evaluate-the-efficacy-and-safety-of-obinutuz-62318.html2025-03-27https://peripazienti.roche.it/it/trials/autoimmune-disorder/gpa.html2019-12-14https://peripazienti.roche.it/it/trials/autoimmune-disorder/a-study-to-evaluate-the-efficacy-and-safety-of-rituxima-33498.html2026-04-01https://peripazienti.roche.it/it/trials/autoimmune-disorder/ibd/a-study-to-assess-the-efficacy-and-safety-of-induction--79083.html2025-10-15https://peripazienti.roche.it/it/trials/autoimmune-disorder/ibd/a-study-to-assess-the-efficacy-and-safety-of-ro7790121--09855.html2025-10-15https://peripazienti.roche.it/it/trials/autoimmune-disorder/ln/a-study-to-evaluate-the-efficacy-and-safety-of-obinutuz-33293.html2025-03-27https://peripazienti.roche.it/it/trials/autoimmune-disorder/ln/a-study-to-evaluate-the-efficacy--safety--and-pharmacok-25573.html2025-03-27https://peripazienti.roche.it/it/trials/autoimmune-disorder/neuromyelitis-optica-spectrum-disorders/efficacy-and-safety-study-of-satralizumab--sa237--as-mo-50688.html2024-09-01https://peripazienti.roche.it/it/trials/autoimmune-disorder/neuromyelitis-optica-spectrum-disorders/a-study-to-evaluate-the-safety-and-efficacy-of-satraliz-27030.html2024-09-18https://peripazienti.roche.it/it/trials/autoimmune-disorder/pnh.html2020-06-18https://peripazienti.roche.it/it/trials/autoimmune-disorder/primary-membranous-nephropathy/a-study-evaluating-the-efficacy-and-safety-of-obinutuzu-42023.html2025-03-25https://peripazienti.roche.it/it/trials/autoimmune-disorder/autoimmune-hepatitis-(aih).html2021-03-16https://peripazienti.roche.it/it/trials/autoimmune-disorder/myasthenia-gravis-iab/a-study-to-evaluate-efficacy--safety--pharmacokinetics--13414.html2025-03-27https://peripazienti.roche.it/it/trials/autoimmune-disorder/neuromyelitis-optica.html2022-01-26https://peripazienti.roche.it/it/trials/autoimmune-disorder/mog-antibody-disease.html2023-02-09https://peripazienti.roche.it/it/trials/autoimmune-disorder/multiple-sclerosis/relapsing-multiple-sclerosis.html2025-10-01https://peripazienti.roche.it/it/trials/eye-disorder/dme/a-study-to-evaluate-the-efficacy-and-safety-of-ro686746-59371.html2024-08-31https://peripazienti.roche.it/it/trials/eye-disorder/dme/a-study-to-evaluate-the-long-term-safety-and-tolerabili-41480.html2024-10-31https://peripazienti.roche.it/it/trials/eye-disorder/dme/a-study-to-investigate-aqueous-humor-and-multimodal-ima-93975.html2024-12-05https://peripazienti.roche.it/it/trials/eye-disorder/glaucoma.html2018-12-20https://peripazienti.roche.it/it/trials/eye-disorder/amd.html2026-02-23https://peripazienti.roche.it/it/trials/eye-disorder/amd/a-study-to-evaluate-the-long-term-safety-and-tolerabili-60381.htmlhttps://peripazienti.roche.it/it/trials/eye-disorder/wamd/a-study-to-evaluate-the-efficacy-and-safety-of-faricima-34628.html2024-08-30https://peripazienti.roche.it/it/trials/eye-disorder/wamd/a-study-to-evaluate-the-efficacy-and-safety-of-faricima-82370.html2024-09-01https://peripazienti.roche.it/it/trials/eye-disorder/rvo.html2021-02-09https://peripazienti.roche.it/it/trials/eye-disorder/rvo/a-study-to-evaluate-the-efficacy-and-safety-of-faricima-25491.htmlhttps://peripazienti.roche.it/it/trials/eye-disorder/uveitic-macular-edema/a-study-to-investigate-ro7200220-in-participants-with-u-27483.html2025-11-25https://peripazienti.roche.it/it/trials/eye-disorder/uveitic-macular-edema/ro7200220-in-participants-with-uveitic-macular-edema-91001.html2025-11-25https://peripazienti.roche.it/it/trials/muscle-and-peripheral-nerve-disease/sma/a-study-of-ro7034067-in-adult-and-pediatric-participants-with-sp.html2025-02-25https://peripazienti.roche.it/it/trials/muscle-and-peripheral-nerve-disease/sma/a-study-to-investigate-the-safety--tolerability--pharmacokinetic1.html2024-08-31https://peripazienti.roche.it/it/trials/muscle-and-peripheral-nerve-disease/dmd/clinical-trial-to-evaluate-the-efficacy--safety--and-to-14306.html2024-08-31https://peripazienti.roche.it/it/trials/muscle-and-peripheral-nerve-disease/dmd/an-open-label-study-to-assess-the-efficacy-and-safety-o-12382.html2025-03-26https://peripazienti.roche.it/it/trials/muscle-and-peripheral-nerve-disease/muscular-dystrophy.html2018-12-20https://peripazienti.roche.it/it/trials/infectious-diseases/hbv/a-study-in-healthy-volunteers-and-in-participants-with-chronic-h.html2024-09-01https://peripazienti.roche.it/it/trials/infectious-diseases/bacterial-infection.html2018-12-20https://peripazienti.roche.it/it/trials/infectious-diseases/covid-19-pneumonia.html2020-04-09https://peripazienti.roche.it/it/trials/neurodegenerative-disorder/ad/a-study-of-crenezumab-versus-placebo-to-evaluate-the-efficacy-an.html2024-09-01https://peripazienti.roche.it/it/trials/neurodegenerative-disorder/ad/a-study-to-evaluate-the-efficacy-and-safety-of-ro7105705-in-pati.html2024-08-31https://peripazienti.roche.it/it/trials/neurodegenerative-disorder/ad/efficacy-and-safety-study-of-gantenerumab-in-participants-with-e.html2024-08-30https://peripazienti.roche.it/it/trials/neurodegenerative-disorder/ad/cread-study--a-study-of-crenezumab-versus-placebo-to-ev-21662.html2024-08-31https://peripazienti.roche.it/it/trials/neurodegenerative-disorder/ad/a-study-to-evaluate-the-safety-and-tolerability-of-long-88018.html2024-09-18https://peripazienti.roche.it/it/trials/neurodegenerative-disorder/ad/a-study-to-evaluate-the-pharmacodynamic--pd--effects-of-20860.html2024-09-18https://peripazienti.roche.it/it/trials/neurodegenerative-disorder/ad/a-study-to-evaluate-the-safety--tolerability--and-effic-66535.html2024-09-18https://peripazienti.roche.it/it/trials/neurodegenerative-disorder/als.html2018-12-20https://peripazienti.roche.it/it/trials/neurodegenerative-disorder/pd/a-study-to-evaluate-the-efficacy-and-safety-of-intraven-35605.html2025-01-22https://peripazienti.roche.it/it/trials/neurodegenerative-disorder/multiple-sclerosis/study-to-evaluate-the-effectiveness-and-safety-of-ocrelizumab-in.html2025-01-16https://peripazienti.roche.it/it/trials/neurodegenerative-disorder/multiple-sclerosis/a-study-of-ocrelizumab-in-participants-with-relapsing-r-56554.html2024-08-31https://peripazienti.roche.it/it/trials/neurodegenerative-disorder/multiple-sclerosis/a-study-of-ocrelizumab-in-children-and-adolescents-with-52808.html2025-03-27https://peripazienti.roche.it/it/trials/neurodegenerative-disorder/multiple-sclerosis/a-phase-iii--non-inferiority--randomized--open-label--p-91560.html2025-03-27https://peripazienti.roche.it/it/trials/neurodegenerative-disorder/hd.html2018-12-20https://peripazienti.roche.it/it/trials/neurodevelopmental-disorder/autism-spectrum-disorder/a-study-of-balovaptan-in-adults-with-autism-spectrum-disorder-wi.html2024-06-21https://peripazienti.roche.it/it/trials/neurodevelopmental-disorder/angelman-syndrome/a-study-to-investigate-the-safety--tolerability--pharma-19556.html2025-02-19https://peripazienti.roche.it/it/trials/neurodevelopmental-disorder/autism/a-12-week-placebo-controlled-study-to-investigate-the-e-88629.html2025-01-29https://peripazienti.roche.it/it/trials/psychiatric-disorder.html2018-12-20https://peripazienti.roche.it/it/trials/psychiatric-disorder/schizophrenia.html2018-12-20https://peripazienti.roche.it/it/trials/respiratory-disorder/ipf/a-study-to-characterize-the-disease-behavior-of-idiopathic-pulmo.html2024-08-30https://peripazienti.roche.it/it/trials/respiratory-disorder/ipf/efficacy--safety--and-tolerability-study-of-pirfenidone-in-combi.html2026-03-26https://peripazienti.roche.it/it/trials/respiratory-disorder/respiratory-other.html2018-12-20https://peripazienti.roche.it/it/trials/respiratory-disorder/asthma.html2018-12-20https://peripazienti.roche.it/it/trials/healthy-volunteers.html2018-12-20https://peripazienti.roche.it/it/trials/kidney-disorder/renal-failure.html2018-12-20https://peripazienti.roche.it/it/trials/metabolic-disorder.html2019-03-22https://peripazienti.roche.it/it/trials/metabolic-disorder/t1d.html2018-12-20https://peripazienti.roche.it/it/trials/metabolic-disorder/t2d.html2018-12-20https://peripazienti.roche.it/it/trials/metabolic-disorder/Liver_Failure.html2018-12-20https://peripazienti.roche.it/it/trials/metabolic-disorder/lysosomal-storage-diseases.html2020-08-06https://peripazienti.roche.it/it/trials/hematologic-diseases/a-study-evaluating-the-efficacy--safety--pharmacokineti-29406.html2024-09-18https://peripazienti.roche.it/it/trials/hematologic-diseases/myelodysplastic-syndrome.html2018-12-20https://peripazienti.roche.it/it/trials/hematologic-diseases/Hemophilia/a-study-of-emicizumab-administered-subcutaneously--sc---47981.html2024-08-30https://peripazienti.roche.it/it/trials/hematologic-diseases/Hemophilia/a-clinical-trial-to-evaluate-prophylactic-emicizumab-ve-59481.html2024-08-31https://peripazienti.roche.it/it/trials/hematologic-diseases/Hemophilia/a-study-to-evaluate-the-efficacy--safety--and-pharmacok-78611.html2024-08-31https://peripazienti.roche.it/it/trials/hematologic-diseases/Hemophilia/hemophilia-a/a-study-to-evaluate-the-safety-and-tolerability-of-prophylactic-.html2023-03-29https://peripazienti.roche.it/it/trials/blood-disorder/sickle-cell-disease/a-study-evaluating-the-efficacy--safety--pharmacokineti-50959.html2025-03-27https://peripazienti.roche.it/it/trials/cardiovascular-disorder.html2022-04-06https://peripazienti.roche.it/it/trials/cardiovascular-disorder/AIS.html2022-04-06https://peripazienti.roche.it/it/trials/Hemophilia/hemophilia-a/a-study-to-evaluate-the-safety--tolerability--pharmacok-88545.html2025-01-15https://peripazienti.roche.it/it/faq.html2020-08-06https://peripazienti.roche.it/it/faq/what-is-a-clinical-trial.html2024-11-13https://peripazienti.roche.it/it/faq/why-should-i-consider-taking-part-in-a-clinical-trial.html2024-11-13https://peripazienti.roche.it/it/faq/roche-in-clinical-trials.html2023-05-09https://peripazienti.roche.it/it/error.html2018-11-22https://peripazienti.roche.it/it/error/404.html2024-10-18https://peripazienti.roche.it/it/error/403.html2024-10-18https://peripazienti.roche.it/it/error/500.html2024-10-18https://peripazienti.roche.it/it/privacy-policy.html2018-11-22https://peripazienti.roche.it/it/glossary-terms.html2019-05-08https://peripazienti.roche.it/it/About.html2019-05-16https://peripazienti.roche.it/it/sitemap.html2019-03-21https://peripazienti.roche.it/it/a-note-about-COVID-19.html2020-04-17https://peripazienti.roche.it/it/disease-area-overview.html2025-03-26https://peripazienti.roche.it/it/new-solr-search.html2024-02-08